We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Oxytocin on Face Perception

This study has suspended participant recruitment.
(We are currently engaged in other behavioral study.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT02091817
First Posted: March 19, 2014
Last Update Posted: July 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ben-Gurion University of the Negev
Information provided by (Responsible Party):
Ilan Shelef, Soroka University Medical Center
January 26, 2014
March 19, 2014
July 2, 2015
November 2013
December 2016   (Final data collection date for primary outcome measure)
Memory performance [ Time Frame: Day 2 (24 hours after encoding) ]
At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw.
Memory performance [ Time Frame: 24 hours after encoding ]
At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are accuracy and eye movements.
Complete list of historical versions of study NCT02091817 on ClinicalTrials.gov Archive Site
Mood measurement [ Time Frame: Day 1 (after oxytocin/placebo uptake) ]
Participants will fill a PANAS mood questionnaire in order to monitor the effects of mood and fatigue of oxytocin/placebo. We will use ANOVA on the total score of the test in order to verify that differences in performance are not due to change in mood or fatigue after substance uptake.
Mood measurement [ Time Frame: Before oxytocin/placebo uptake, and 45 min. after ]
Participants will fill a PANAS mood questionnaire just before oxytocin/placebo uptake, and 45 minutes after oxytocin/placebo uptake, in order to monitor the effects of mood and fatigue of oxytocin/placebo.
Not Provided
Not Provided
 
The Effect of Oxytocin on Face Perception
The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia
The purpose of this study is to determine whether oxytocin affect face perception
Not Provided
Interventional
Early Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
  • Healthy
  • Congenital Prosopagnosia
  • Drug: Oxytocin
    Intervention will be examined on control group, and on experimental group as well.
    Other Name: syntocinon
  • Drug: Placebo
    Placebo will be given to control group and experimental group as well.
  • Control group
    Control group will be administered oxytocin and placebo, in a double-blind randomized order.
    Interventions:
    • Drug: Oxytocin
    • Drug: Placebo
  • Experimental: congenital prosopagnosia
    Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
    Interventions:
    • Drug: Oxytocin
    • Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
100
December 2017
December 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • normal or corrected to normal vision

Exclusion Criteria:

  • minors
  • pregnancy (according to a pregnancy test taken by subjects prior to participation)
  • a history of asthma or nasal polyps
  • cardiac disorders
  • hyponatremia
  • acute or chronic renal insufficiency
  • liver cirrhosis
  • neurological disease
  • other chronic disease
  • dementia, or lack of judgment
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT02091817
sor010712ctil
ISF, 384/10 ( Other Grant/Funding Number: israeli Science Foundation )
No
Not Provided
Not Provided
Ilan Shelef, Soroka University Medical Center
Soroka University Medical Center
Ben-Gurion University of the Negev
Principal Investigator: Shelef Ilan, MD Soroka University Medical Center
Principal Investigator: Galia Avidan, Ph.D Ben-Gurion University of the Negev
Soroka University Medical Center
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP